Oragenics Expands Phase IIa Trial for Concussion Treatment, Doses First Patients at Second Site

Oragenics Inc. (NYSE American: OGEN) announced it has begun active enrollment at a second clinical site for its Phase IIa trial evaluating ONP-002, a novel intranasal treatment for concussion and mild traumatic brain injury (mTBI). The company reported that four patients have already been dosed at its initial site in Australia, marking a step forward in the development of what could become a first-in-class therapy for these conditions.

The expansion to a second site accelerates patient recruitment and brings Oragenics closer to its planned data readout by the end of 2026. ONP-002 is designed to be delivered via the company's proprietary intranasal technology, which targets the brain directly and may offer advantages over existing treatments that often rely on systemic administration. According to Oragenics, the intranasal delivery platform has potential applications across multiple neurological disorders, including Parkinson's disease, Alzheimer's disease, PTSD, and anxiety disorders.

Concussion and mTBI represent a significant unmet medical need, with millions of cases occurring annually worldwide. Current standard of care focuses on rest and symptom management, with no FDA-approved pharmacological treatments specifically indicated for concussion. ONP-002 aims to address this gap by reducing inflammation and protecting neurons after injury. The Phase IIa trial is designed to evaluate safety, tolerability, and early efficacy signals in patients with acute concussion.

Oragenics is a clinical-stage biotechnology company committed to developing brain-targeted therapeutics. Its lead candidate, ONP-002, has shown promise in preclinical studies, and the company plans to follow the Australian Phase IIa trial with a U.S. Phase 2b study. For more information about Oragenics and its pipeline, visit oragenics.com.

The successful dosing at a second site is a positive indicator of trial momentum. Analysts note that advancing enrollment is critical for meeting the 2026 data readout timeline. The company's intranasal platform, if successful, could revolutionize treatment for multiple neurological conditions by delivering therapeutics directly to the brain, bypassing the blood-brain barrier more efficiently than traditional methods.

Investors and stakeholders can find the latest news and updates regarding Oragenics in the company’s newsroom at https://ibn.fm/OGEN. The full press release detailing the trial expansion is available at https://ibn.fm/SA2Fu.

Oragenics' progress in the Phase IIa trial underscores the potential for innovative treatments in the neurology space. With no approved pharmacotherapies for concussion, a successful ONP-002 could capture a substantial market and improve outcomes for patients worldwide. The company remains focused on addressing significant unmet medical needs through its intranasal delivery platform.